Azithromycin in the treatment of pneumonia caused by Chlamydia pneumoniae: Report of a case

J. H. Wang, J. H. Wang, Y. C. Liu, Y. S. Chen, M. Y. Yen, S. R. Wann, D. L. Cheng

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We report a 67-year-old male with pneumoniae in which Chlamydia pneumoniae was identified by serologic studies as the causative agent. After initial treatment failure with amoxicillin + clavulanic acid, pneumonia was successfully treated with the administration or oral azithromycin, 500 mg per day, for three days. Azithromycin is a new macrolide which has a long half-life and superior action to erythromcyin. It provides a new and alternative choice in the treatment of Chlamydia pneumoniae infection in the future.

Original languageEnglish
Pages (from-to)642-644
Number of pages3
JournalJournal of the Formosan Medical Association = Taiwan yi zhi
Volume93
Issue number7
Publication statusPublished - 1994
Externally publishedYes

Fingerprint

Chlamydophila pneumoniae
Azithromycin
Pneumonia
Amoxicillin-Potassium Clavulanate Combination
Chlamydia Infections
Macrolides
Treatment Failure
Oral Administration
Half-Life
Therapeutics

Keywords

  • azithromycin
  • Chlamydia pneumoniae

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Azithromycin in the treatment of pneumonia caused by Chlamydia pneumoniae : Report of a case. / Wang, J. H.; Wang, J. H.; Liu, Y. C.; Chen, Y. S.; Yen, M. Y.; Wann, S. R.; Cheng, D. L.

In: Journal of the Formosan Medical Association = Taiwan yi zhi, Vol. 93, No. 7, 1994, p. 642-644.

Research output: Contribution to journalArticle

Wang, J. H. ; Wang, J. H. ; Liu, Y. C. ; Chen, Y. S. ; Yen, M. Y. ; Wann, S. R. ; Cheng, D. L. / Azithromycin in the treatment of pneumonia caused by Chlamydia pneumoniae : Report of a case. In: Journal of the Formosan Medical Association = Taiwan yi zhi. 1994 ; Vol. 93, No. 7. pp. 642-644.
@article{59bb0335d46b434ebab2c1a5926accb7,
title = "Azithromycin in the treatment of pneumonia caused by Chlamydia pneumoniae: Report of a case",
abstract = "We report a 67-year-old male with pneumoniae in which Chlamydia pneumoniae was identified by serologic studies as the causative agent. After initial treatment failure with amoxicillin + clavulanic acid, pneumonia was successfully treated with the administration or oral azithromycin, 500 mg per day, for three days. Azithromycin is a new macrolide which has a long half-life and superior action to erythromcyin. It provides a new and alternative choice in the treatment of Chlamydia pneumoniae infection in the future.",
keywords = "azithromycin, Chlamydia pneumoniae",
author = "Wang, {J. H.} and Wang, {J. H.} and Liu, {Y. C.} and Chen, {Y. S.} and Yen, {M. Y.} and Wann, {S. R.} and Cheng, {D. L.}",
year = "1994",
language = "English",
volume = "93",
pages = "642--644",
journal = "Journal of the Formosan Medical Association",
issn = "0929-6646",
publisher = "Elsevier Science Publishers B.V.",
number = "7",

}

TY - JOUR

T1 - Azithromycin in the treatment of pneumonia caused by Chlamydia pneumoniae

T2 - Report of a case

AU - Wang, J. H.

AU - Wang, J. H.

AU - Liu, Y. C.

AU - Chen, Y. S.

AU - Yen, M. Y.

AU - Wann, S. R.

AU - Cheng, D. L.

PY - 1994

Y1 - 1994

N2 - We report a 67-year-old male with pneumoniae in which Chlamydia pneumoniae was identified by serologic studies as the causative agent. After initial treatment failure with amoxicillin + clavulanic acid, pneumonia was successfully treated with the administration or oral azithromycin, 500 mg per day, for three days. Azithromycin is a new macrolide which has a long half-life and superior action to erythromcyin. It provides a new and alternative choice in the treatment of Chlamydia pneumoniae infection in the future.

AB - We report a 67-year-old male with pneumoniae in which Chlamydia pneumoniae was identified by serologic studies as the causative agent. After initial treatment failure with amoxicillin + clavulanic acid, pneumonia was successfully treated with the administration or oral azithromycin, 500 mg per day, for three days. Azithromycin is a new macrolide which has a long half-life and superior action to erythromcyin. It provides a new and alternative choice in the treatment of Chlamydia pneumoniae infection in the future.

KW - azithromycin

KW - Chlamydia pneumoniae

UR - http://www.scopus.com/inward/record.url?scp=0028598698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028598698&partnerID=8YFLogxK

M3 - Article

C2 - 7866068

AN - SCOPUS:0028598698

VL - 93

SP - 642

EP - 644

JO - Journal of the Formosan Medical Association

JF - Journal of the Formosan Medical Association

SN - 0929-6646

IS - 7

ER -